quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:00:00·1d
PRRelease
SAB Biotherapeutics Inc. logo

SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026

SABS· SAB Biotherapeutics Inc.
Health Care
Original source

Companies

  • SABS
    SAB Biotherapeutics Inc.
    Health Care

Recent analyst ratings

  • Apr 3UpdateRodman & Renshaw$13.00
  • Apr 2UpdateRodman & Renshaw$13.00
  • Dec 19UpdateGuggenheim$15.00
  • Sep 17UpdateLeerink Partners$7.00
  • May 14UpdateH.C. Wainwright$10.00
  • Oct 9UpdateCraig Hallum$11.00

Related

  • SEC1d
    SAB Biotherapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
  • PR8d
    SAB BIO to Present Additional Data Supporting the Unique Profile of SAB-142 at the 2026 Immunology of Diabetes Society Congress
  • ANALYST20d
    Rodman & Renshaw initiated coverage on SAB BIO with a new price target
  • ANALYST21d
    Rodman & Renshaw initiated coverage on SAB BIO with a new price target
  • SEC23d
    SEC Form S-8 filed by SAB Biotherapeutics Inc.
  • INSIDER29d
    SEC Form 4 filed by Kropotova Alexandra
  • SEC31d
    Amendment: SEC Form SCHEDULE 13D/A filed by SAB Biotherapeutics Inc.
  • PR35d
    SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022